start with the financial results. Consolidated revenues for 2009-10 was Rs. 70,277 million. Excluding revenues from sumatriptan — your Company’s Authorized Generic version of Imitrex® which was launched in 2008-09 — revenue grew by 9%. In US dollar terms, 2009-10 revenue was US$ 1.56 billion. I am happy to inform you that the Company’s revenue has been rising at a CAGR of 23% over the last decade. That is a creditable performance by any standard. Your Company’s EBITDA of Rs. 15,828 million was the
Words: 111729 - Pages: 447
Women Entrepreneurs in SMEs: Bangladesh Perspective Sponsored by: SME Foundation Conducted by: MIDAS November 2009 Table of Contents Acronyms List of Tables and Figures Executive Summary Chapter 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Chapter 2.0 2.1 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.1.6 2.2 2.3 2.4 2.5 2.5.1 2.5.2 2.6 3.0 4.0 4..1 4..2 5.0 5.1 5.2 5.3 5.4 6.0 6.1 6.2 6.3 6.4 6.4.1 6.5 6.6 6.7 6.7.1 6.7.2 7.0 7.1 Introduction Statement of the problem Significance of the study Objective of the
Words: 136702 - Pages: 547
